Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
| PHM Stock | EUR 75.50 0.10 0.13% |
About 51% of Pharma Mar's investor base is interested to short. The analysis of current outlook of investing in Pharma Mar SA suggests that many traders are impartial regarding Pharma Mar's prospects. The current market sentiment, together with Pharma Mar's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharma Mar SA stock news signals to limit their universe of possible portfolio assets.
Pharma |
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Marketscreener.com
Read at news.google.com
 |
Pharma Mar Fundamental Analysis
We analyze Pharma Mar's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Pharma Mar is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Pharma Mar SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharma Mar stock to make a market-neutral strategy. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics with similar companies.
Peers
Pharma Mar Related Equities
| ROVI | Laboratorios Farmaceuticos | 0.56 |
| ||
| ATRY | Atrys Health | 1.24 |
| ||
| ORY | Oryzon Genomics | 1.95 |
|
Complementary Tools for Pharma Stock analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets |